Year-end Sale % OFF 
Abstract
The COMPASS-3 trial is a prospective, multi-center study evaluating a goal based approach to combinational therapy in PAH. As prognosis ultimately depends on the degree of right ventricular (RV) dysfunction, RV remodeling will be evaluated by serial cardiac MRIs and correlated with clinical, invasive and non-invasive parameters. Reported herein are the baseline characteristics of the initial 47 enrolled patients as of August 1 2008.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
